July 8, 2025 10:26 AM EDT
News Briefing

Re­cur­sion takes full rights to rare ge­net­ic dis­or­der drug; CStone out-li­cens­es can­cer drug in Eu­rope

ENDPOINTS

Plus, news about Basilea, BAR­DA, In­ven­ti­va and CT­TQ:

Re­cur­sion buys full rights to oral drug: The AI-dri­ven biotech, which

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Ex­clu­sive: Start­up rais­es $45M for uni­ver­sal flu vac­cines made with mR­NA

Shell com­pa­ny Con­cen­tra has found its rhythm, with Car­go Ther­a­peu­tics as its lat­est buy­out tar­get

ProKid­ney's stock shoots high­er af­ter mixed Phase 2 da­ta

Trump hints at tar­iff grace pe­ri­od for phar­ma com­pa­nies to bring man­u­fac­tur­ing to US

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times